DBV FP : 17:00 ET Q3 call: Expects existing cash to fund operations into Q3 2027, based on an updated, milestone-driven spending plan following the BLA submission. Q3-end cash was $165.7M, including $50M of gross proceeds from ADS sales to RA Capital; commercial investment will be paced to regulatory developments while funding review and potential launch requirements.
- All launch and manufacturing plans assume priority review for Viaskin Peanut in ages 4–7—not a longer review timeline. Priority review has been requested but not granted; management characterized it as its “hope” rather than a firm expectation, while remaining comfortable that remediation and inspection preparation can fit the tighter clock.
- Targets February 1, 2027, for pre-approval inspection readiness, after Fareva’s expected remediation completion. FDA reinspection has not yet been scheduled. Management is comfortable with remediation progress and the buffer between reinspection and the pre-approval inspection; mock inspections will precede readiness. The warning letter arose from a separate veterinary manufacturing process, but quality-system findings have site-wide implications.
- Expects the ages 1–3 BLA submission in 2027, with timing and submission structure still being discussed with FDA. The same FDA team will review both applications, so DBV favors a coordinated, sequential approach to avoid creating a bottleneck or slowing the ages 4–7 review. FDA indicated that starting the toddler review shortly after the older-child review would leverage shared content and learnings.
- Launch remains dependent on Fareva capacity: a second manufacturing unit is needed for demand in the outer years of management’s forecast, but establishing a facility takes approximately three years and is explicitly not a near-term backup. The current plan is to remediate Fareva and launch from that site.
- Commercial planning contemplates 50–70 sales representatives targeting approximately 4,500 US allergists, alongside parent outreach and payer engagement. Account managers are already speaking with major US payers; salesforce hiring and larger launch-inventory investments come later. Management emphasized that a potential blockbuster requires roughly 18 months of preparation, not six weeks.
- Comfort Toddlers completed recruitment in Q2 2026 and requires six months of supplemental safety follow-up. Management expects results consistent with the existing approximately 2,000-patient safety database and described the anticipated announcement as largely “check-the-box”; results are not yet available. FDA discussions will determine whether these data enter the initial toddler BLA or a subsequent safety update.
- Potential priority review for ages 1–3 could be supported by the accelerated-approval pathway, but FDA has made no commitment. Whether one breakthrough designation can support priority review for two separate BLAs remains untested.
Related: DBV.FR